News Release

May 30, 2025

Perseus Proteomics, Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

PPMX-T003: Announcement of Publication of Paper Co-authored by Hyogo Medical University and Perseus Proteomics on the results of basic studies for the regulation of vascular remodeling.

Perseus Proteomics Inc. (“the Company”, President & CEO: Takuya Yokokawa, HQ: Tokyo) is pleased to announce that a research paper reported on basic research related to PPMX-T003, which is under clinical development. This study demonstrates the potential of anti-transferrin receptor 1 (TfR1) antibodies as therapeutic agents for vascular remodeling*. The findings have been published online in the international scientific journal "Journal of Molecular and Cellular Cardiology." This paper is co-authored by researchers including Yoshiro Naito, Lecturer (part-time) (former Associate Professor) at Hyogo Medical University, and our CTO, Executive Officer Tadashi Matsuura.

* Vascular remodeling refers to morphological and functional changes in the structure of blood vessels, especially the vessel wall. It is a medical term describing a phenomenon or process observed in various cardiovascular and chronic diseases, rather than indicating a specific "disease."

[Paper information]
Title: Anti-transferrin receptor 1 antibody reduces angiotensin II-induced vascular remodeling
Journal: Journal of Molecular and Cellular Cardiology
Author: Yoshiro Naito, Takeshi Tsujino, Tadashi Matsuura, Masanori Asakura, Tohru Masuyama, Masaharu Ishihara

URL: https://www.jmcc-online.com/article/S0022-2828(25)00088-4/fulltext

END